Treatment: Immunomodulatory drugs and rituximab

P. A. Hart, Suresh T Chari

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Autoimmune pancreatitis (AIP) is the pancreatic manifestation of the multiorgan syndrome currently referred to as IgG4-related disease (IgG4-RD). Although AIP and the other organ manifestations of IgG4-RD characteristically respond to steroid treatment, a subset of individuals has disease that is difficult to control, including those who are unable to tolerate high-dose steroids, develop steroid dependence, or have frequent relapses despite maintenance treatment. Existing data suggest that immunomodulatory agents and rituximab (RTX) may be helpful for some to achieve and maintain remission; however, additional studies demonstrating efficacy are needed.

Original languageEnglish (US)
Title of host publicationAutoimmune Pancreatitis
PublisherSpringer Berlin Heidelberg
Pages155-160
Number of pages6
ISBN (Print)9783642550867, 9783642550850
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment: Immunomodulatory drugs and rituximab'. Together they form a unique fingerprint.

  • Cite this

    Hart, P. A., & Chari, S. T. (2015). Treatment: Immunomodulatory drugs and rituximab. In Autoimmune Pancreatitis (pp. 155-160). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-55086-7_23